^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Bond Oracle HER2 IHC System

    Company:
    Danaher Corp
    Type:
    FDA Approved
    Related tests:
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 overexpression-Breast Cancer-trastuzumab]

    Source:
    FDA
    Test:

    Bond Oracle HER2 IHC System

    Excerpt:
    Herceptin is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer.
    Secondary therapy:
    carboplatin + docetaxel; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; docetaxel + doxorubicin hydrochloride + cyclophosphamide; paclitaxel